Keith Flaherty

Medicine, University of Pennsylvania, United States of America

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Oncology > Genitourinary Cancers (since 16 October 2007)

All recent recommendations

• 3.0
  Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
  Recommended by Keith Flaherty with Stephen Keefe
  
• 3.0
  Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.
  Recommended by Keith Flaherty with Stephen Keefe
  
• 3.0
  Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survival.
  Recommended by Keith Flaherty
  
• 3.0
  Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
  Recommended by Keith Flaherty
  
• 3.0
  Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
  Recommended by Keith Flaherty